News | Cardiovascular Ultrasound | February 18, 2025

UltraSight Expands Access to Cardiac Monitoring with AI

In a new study, non-sonographers to use UltraSight Real-Time Guidance for patients that require echocardiogram.


Feb. 11, 2025  — UltraSight, a company committed to enhancing the efficiency and productivity of cardiac ultrasound, recently announced support from Bristol Myers Squibb (BMS) for a study that aims to improve access to echocardiographic assessments for patients with obstructive hypertrophic cardiomyopathy (oHCM).

Cardiac ultrasound is routinely used as an essential tool in the diagnosis and management of oHCM.

“UltraSight was founded with the goal of giving clinicians the ability to scan patients, wherever patients may be,” said Davidi Vortman, CEO of UltraSight. “By applying the power of machine learning to imaging, our aim is to streamline patient cardiac workflows with UltraSight real-time guidance for better, more efficient, and effective care. We are thrilled to receive support from BMS on this study with the goal of evaluating how this technology could help patients in need of consistent and reliable cardiac follow-up.”

The study will be launched at Cleveland Clinic and will focus on oHCM patients with the aim to validate the quality and accuracy of the monitoring echocardiograms performed by non-sonographers using UltraSight’s Real-Time Guidance software.

UltraSight’s Real-Time Guidance software provides real-time assistance for healthcare providers, guiding them to acquire diagnostic-quality echocardiography images. This approach is designed to optimize and streamline cardiac monitoring and other clinical workflows, enabling non-sonographers to achieve consistent, diagnostic-quality ultrasound thus improving patient access, operational efficiency, and patient care. By putting cardiac ultrasound in the hands of any medical professional, UltraSight’s software can help expand access to care, bringing cardiac ultrasound to more hospitals and cardiology clinics across the country.

“At Bristol Myers Squibb, we are committed to forging the path to improve cardiac care through innovative science,” said Cecilia Marta, Vice President, US Medical Cardiovascular. “This support of UltraSight  exemplifies our commitment to transforming patients’ lives through science by supporting cutting edge research.

Recruitment for the trial will begin in 2025. Please check https://clinicaltrials.gov/ for updates.

For more information about UltraSight, visit  https://ultrasight.com/. For more information about Bristol Myers Squibb, visit https://www.bms.com/.


Related Content

News | Cardiovascular Ultrasound

March 24, 2025 — FUJIFILM Healthcare Americas Corp. and Us2.ai have partnered to equip Fujifilm’s LISENDO 800 ...

Home March 24, 2025
Home
News | Cardiovascular Ultrasound

May 30, 2024 — A recent study published in the European Heart Journal highlights the significant enhancements that the ...

Home May 30, 2024
Home
News | Cardiovascular Ultrasound

April 5, 2024 — Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound ...

Home April 05, 2024
Home
News | Cardiovascular Ultrasound

August 24, 2023 —Royal Philips, a global leader in health technology, highlighted how it integrates AI in cardiac ...

Home August 24, 2023
Home
News | Cardiovascular Ultrasound

July 27, 2023 —UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial ...

Home July 27, 2023
Home
Feature | Cardiovascular Ultrasound

February 10, 2023 — GE HealthCare, a leading global precision care innovator, announced that it has signed an agreement ...

Home February 10, 2023
Home
Feature | Cardiovascular Ultrasound | By Paul M Bojarski

Sudden cardiac arrest is a complex and challenging medical emergency because it can occur anywhere at any time and is ...

Home August 23, 2022
Home
News | Cardiovascular Ultrasound

August 9, 2022 — Butterfly Medical, an Israeli medical device company developing a novel minimally invasive solution to ...

Home August 09, 2022
Home
News | Cardiovascular Ultrasound

July 20, 2022 — Teleflex Incorporated, a leading global provider of medical technologies, announced the first patient ...

Home July 20, 2022
Home
Sponsored Content | Videos | Cardiovascular Ultrasound

Enhanced features on the Philips EPIQ CVx ultrasound system provide a next level photorealistic 3D rendering, making it ...

Home July 20, 2022
Home
Subscribe Now